| 137.32 2.34 (1.73%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 163.73 |
1-year : | 191.23 |
| Resists | First : | 140.17 |
Second : | 163.73 |
| Pivot price | 131.76 |
|||
| Supports | First : | 130.27 |
Second : | 124.16 |
| MAs | MA(5) : | 134.1 |
MA(20) : | 130.58 |
| MA(100) : | 139.35  |
MA(250) : | 129.48 |
|
| MACD | MACD : | 0.3 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 77.4 |
D(3) : | 69.9 |
| RSI | RSI(14): 59.4 |
|||
| 52-week | High : | 155.35 | Low : | 96.8 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ A ] has closed below upper band by 8.6%. Bollinger Bands are 17.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 140.35 - 140.89 | 140.89 - 141.43 |
| Low: | 134.66 - 135.31 | 135.31 - 135.96 |
| Close: | 136.29 - 137.27 | 137.27 - 138.25 |
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Fri, 26 Jul 2024
Agilent Technologies, Inc. (A): Hedge Funds Are Bullish on This Scientific Instruments Stock Now - Insider Monkey
Fri, 26 Jul 2024
Healthcare of Ontario Pension Plan Trust Fund Decreases Stock Position in Agilent Technologies, Inc. (NYSE:A) - MarketBeat
Thu, 25 Jul 2024
Agilent: Making A Move To Ignite Some Growth (NYSE:A) - Seeking Alpha
Thu, 25 Jul 2024
Agilent Technologies (NYSE:A) Shares Gap Up to $133.42 - Defense World
Wed, 24 Jul 2024
Agilent Technologies Inc. stock rises Wednesday, outperforms market - MarketWatch
Wed, 24 Jul 2024
Agilent acquires Canada pharmaceutical manufacturing company - BizWest
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 292 (M) |
| Shares Float | 291 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 92.3 (%) |
| Shares Short | 4,150 (K) |
| Shares Short P.Month | 4,420 (K) |
| EPS | 4.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 21.3 |
| Profit Margin | 18.8 % |
| Operating Margin | 23.7 % |
| Return on Assets (ttm) | 7.8 % |
| Return on Equity (ttm) | 20.7 % |
| Qtrly Rev. Growth | -8.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 22.58 |
| EBITDA (p.s.) | 5.51 |
| Qtrly Earnings Growth | 2.9 % |
| Operating Cash Flow | 1,900 (M) |
| Levered Free Cash Flow | 924 (M) |
| PE Ratio | 32.54 |
| PEG Ratio | 5.1 |
| Price to Book value | 6.44 |
| Price to Sales | 6.07 |
| Price to Cash Flow | 21.08 |
| Dividend | 0.23 |
| Forward Dividend | 0 |
| Dividend Yield | 0.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|